FDA Approves Remdesivir for Babies and Young Children to Treat COVID-19
The US Food and Drug Administration announced that full approval will be granted to Remdesivir, a COVID-19 drug to treat babies and children aged 28 days and older. Reports show that Remdesivir causes severe side effects that includean dysfunction, septic shock and kidney and liver damage.